MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
Capricor Therapeutics Operating Income 2011-2026 | CAPR
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Capricor Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -24.1 M | -29.7 M | -20.9 M | -13.7 M | -7.73 M | -15.3 M | -12.9 M | -17 M | -12.6 M | -6.02 M | -6.9 M | -2.1 M | -4.9 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -2.1 M | -29.7 M | -13.4 M |
Quarterly Operating Income Capricor Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -26.3 M | -27.7 M | -25 M | - | -13 M | -11.6 M | -10.3 M | - | -6.86 M | -7.75 M | -8.18 M | - | -6.48 M | -7.32 M | -7.83 M | - | -4.31 M | -5.08 M | -5.16 M | - | -3.91 M | -3.49 M | -2.11 M | - | -1.63 M | -2.07 M | -2.56 M | - | -4.17 M | -4.16 M | -3.69 M | - | -2.64 M | -3.38 M | -3.57 M | - | -5.24 M | -4.61 M | -4.21 M | - | -2.85 M | -3.06 M | -3.41 M | - | -1.49 M | -1.48 M | -1.19 M | - | -1.49 M | -1.62 M | -1.43 M | - | -576 K | -774 K | -770 K | - | -1.16 M | -880 K | -1.2 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -576 K | -27.7 M | -5.5 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alector
ALEC
|
-156 M | $ 2.08 | -14.4 % | $ 214 M |  USA |
 |
Acer Therapeutics
ACER
|
-24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Altimmune
ALT
|
-103 M | $ 4.2 | -2.67 % | $ 298 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
55.4 M | $ 20.24 | -3.44 % | $ 2.55 B | USA |
 |
Aprea Therapeutics
APRE
|
-15.5 M | $ 0.88 | -3.72 % | $ 3.18 M | USA |
 |
Aptevo Therapeutics
APVO
|
-24.6 M | $ 7.2 | -1.64 % | $ 1.99 M | USA |
 |
Aquestive Therapeutics
AQST
|
-30.8 M | $ 4.1 | 2.37 % | $ 356 M | USA |
 |
AgeX Therapeutics
AGE
|
-9.89 M | - | -10.17 % | $ 12.2 K | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-95.7 M | $ 8.35 | 1.46 % | $ 225 M |  Israel |
 |
Ardelyx
ARDX
|
-41 M | $ 6.37 | -2.75 % | $ 1.54 B | USA |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
argenx SE
ARGX
|
-349 M | $ 756.71 | -1.33 % | $ 25 B |  Niderland |
 |
Armata Pharmaceuticals
ARMP
|
-40.9 M | $ 10.91 | 1.58 % | $ 394 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-12.2 M | $ 25.33 | -6.1 % | $ 3.22 B | USA |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Artelo Biosciences
ARTL
|
-11.4 M | $ 1.15 | -3.36 % | $ 2.32 M | USA |
 |
Arvinas
ARVN
|
-118 M | $ 12.97 | -2.3 % | $ 920 M | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
98.3 M | $ 61.74 | -2.42 % | $ 8.26 B | USA |
 |
Ascendis Pharma A/S
ASND
|
-452 M | $ 231.56 | -0.83 % | $ 5 B |  Danmark |
 |
Actinium Pharmaceuticals
ATNM
|
-42.1 M | $ 1.17 | -0.85 % | $ 35.2 M | USA |
 |
Atossa Therapeutics
ATOS
|
-31.4 M | $ 4.39 | -0.9 % | $ 553 M | USA |
 |
Atara Biotherapeutics
ATRA
|
-83.4 M | $ 5.01 | -7.47 % | $ 37.5 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
33.2 M | $ 14.14 | -0.21 % | $ 1.9 B |  Canada |
 |
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K | USA |
 |
Autolus Therapeutics plc
AUTL
|
-241 M | $ 1.68 | -1.75 % | $ 429 M | Britain |
 |
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M | Canada |
 |
Atea Pharmaceuticals
AVIR
|
-193 M | $ 4.69 | 0.21 % | $ 395 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-139 M | - | - | $ 86.2 M | USA |
 |
AIkido Pharma
AIKI
|
-11.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
-51.4 M | $ 4.54 | 2.44 % | $ 387 M | USA |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
Axon Enterprise
AXON
|
58.5 M | $ 570.5 | 5.18 % | $ 43.2 B | USA |
 |
Axsome Therapeutics
AXSM
|
-167 M | $ 162.28 | -0.98 % | $ 8.07 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-47.6 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aytu BioScience
AYTU
|
-7.83 M | $ 2.56 | -0.58 % | $ 16.1 M | USA |
 |
Aileron Therapeutics
ALRN
|
-65.1 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-58.1 M | - | - | $ 2.17 B | USA |